Drug Approval | March 09, 2023
Alembic receives USFDA final approval for Prazosin Hydrochloride Capsules
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Subscribe To Our Newsletter & Stay Updated
